X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
RETHYMIC® (allogeneic processed thymus tissue-agdc) is a novel one-time tissue-based regenerative therapy used for immune reconstitution in pediatric patients with congenital athymia.
Lead Product(s): Allogeneic Processed Thymus Tissue-agdc
Therapeutic Area: Rare Diseases and Disorders Product Name: Rethymic
Highest Development Status: ApprovedProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Enzyvant Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Merger December 06, 2022
Details:
RVT-1201 (rodatristat ethyl) is a tryptophan hydroxylase inhibitor designed to reduce body’s peripheral production of serotonin, in preclinical study comparing rodatristat ethyl monotherapy and in combination with ambrisentan, in an animal model of PAH.
Lead Product(s): Rodatristat Ethyl,Ambrisentan
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: RVT-1201
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 06, 2022
Details:
Results of in vivo studies presented at ISHLT demonstrate that aerosolized ALTA-2530 achieved distribution to distal regions of lung. In separate in vitro studies, ALTA-2530 demonstrated a significantly greater binding affinity for IL-1 type 1 receptor.
Lead Product(s): ALTA-2530
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: ALTA-2530
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 02, 2022
Details:
Results of in vivo preclinical studies measuring lung distribution of aerosolized ALTA-2530, an IL-1 receptor antagonist (IL-1Ra) in development for treatment of bronchiolitis obliterans syndrome, a life-threatening form of CLAD.
Lead Product(s): ALTA-2530
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: ALTA-2530
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Sumitovant Biopharma
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 25, 2022
Details:
ELEVATE 2 will test the ability of rodatristat to reduce the peripheral production of serotonin through its unique mechanism of tryptophan hydroxylase (TPH) inhibition in order to improve PAH symptoms.
Lead Product(s): Rodatristat Ethyl
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 20, 2021
Details:
The studies demonstrated enhanced distribution of rodatristat ethyl in lung tissue consistent with levels associated with disease modification in preclinical models and also demonstrated minimal brain exposure supporting a lack of impact on brain serotonin levels.
Lead Product(s): Rodatristat Ethyl
Therapeutic Area: Cardiology/Vascular Diseases Product Name: RVT-1201
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 05, 2020
Details:
This acquisition expands Altavant’s pipeline to include OSP-101, a novel inhaled interleukin-1 receptor antagonist (IL-1Ra) with orphan drug designation from the U.S. Food and Drug Administration.
Lead Product(s): OSP-101
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Undisclosed
Partner/Sponsor/Collaborator: Altavant Sciences
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition January 08, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
